Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterase agents block the breakdown of acetylcholine by inhibiting cholinesterase enzymes, causing acetylcholine to accumulate in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions at their respective receptors. The degree of enhancement depends on whether the agent forms reversible or irreversible bonds with the enzyme.

Enzyme aging occurs when the phosphorylated enzyme complex loses an alkyl group, making it resistant to hydrolytic regeneration. Once aging happens, cholinesterase reactivators like pralidoxime become ineffective because they cannot restore enzyme function. This irreversible change means treatment must occur before aging begins to successfully reactivate the enzyme.

Pralidoxime binds to the anionic site of acetylcholinesterase through its charged quaternary nitrogen, while its oxime end reacts with the phosphorus atom of the organophosphate-enzyme complex. This interaction causes the complex to diffuse away from the enzyme, restoring its catalytic function. The reactivation is only effective before the enzyme undergoes aging.

Atropine is a cholinergic antagonist that blocks muscarinic receptors, effectively reversing muscarinic symptoms like excessive salivation and muscle contractions. However, atropine cannot reverse nicotinic effects such as muscle paralysis because it does not block nicotinic receptors. Nicotinic symptoms require cholinesterase reactivators or supportive measures like mechanical ventilation.

Treatment involves multiple approaches: gastric lavage removes ingested poison, maintaining hydration and blood pressure supports vital functions, and airway patency ensures adequate respiration. Intravenous atropine manages muscarinic symptoms, while diazepam controls convulsions. In organophosphate cases, cholinesterase reactivators like pralidoxime restore neuromuscular transmission if administered before enzyme aging occurs.

Reversible anticholinesterase agents form weak, temporary bonds with cholinesterase enzymes, allowing the enzyme to regenerate relatively quickly. Irreversible agents, such as organophosphates, form strong covalent bonds that persist much longer. Irreversible agents pose greater toxicity risk because the enzyme cannot easily recover function, leading to prolonged acetylcholine accumulation and severe cholinergic effects.

Organophosphates interact covalently with acetylcholinesterase, forming a phosphorylated enzyme complex that is highly stable. Unlike carbamylated complexes from reversible agents, the phosphorylated complex breaks down very slowly. Over time, the complex undergoes aging by losing an alkyl group, creating a form completely resistant to hydrolytic regeneration and permanently inactivating the enzyme.